The authors concluded that postmenopausal women taking thyrotropin-suppressive therapy may be at greatest risk of osteoporosis, but studies generally found no increased risk in premenopausal women and men. Poor reporting of review methods, an inadequate quality assessment of the included studies, and the reliance upon studies with small sample sizes make commenting on the reliability of the conclusions difficult.
Data extraction
The authors did not state how the data were extracted for the review, or how many reviewers performed the data extraction. For each study, where possible, the BMD at end point was presented for each treatment group (generally as BMD z-scores) along with the level of statistical significance of the treatment difference.
Methods of synthesis
How were the studies combined?
The studies were combined in a narrative.
How were differences between studies investigated?
The studies were grouped according to study design and the characteristics of the participants (premenopausal women, postmenopausal women and men); the results were discussed separately for these subgroups.
Results of the review
The authors stated that 21 studies were included, and that these included 6 prospective studies and 17 cross-sectional studies with and without control groups. The data extraction tables list 6 reference numbers for longitudinal studies and 18 unique reference numbers for cross-sectional studies; however, 2 studies are listed as both longitudinal and crosssectional. There appeared to be no obvious explanation for these discrepancies.
The sample size ranged from 5 to 52.
Twelve cross-sectional studies (n=304) and 4 prospective studies (n=67) evaluated effects in premenopausal women. Fourteen cross-sectional studies (n=326) and 4 prospective studies (n=132) evaluated effects in postmenopausal women. Eight cross-sectional studies (n=147) and 1 prospective study (n=9) evaluated effects in men.
All studies.
Four of 6 prospective studies reported that TSH-suppressive thyroxine therapy was associated with a significant decrease in BMD from baseline. Four of 17 cross-sectional studies reported a significant difference between patients with DTC and controls.
Premenopausal women (16 studies).
Two of the 12 cross-sectional studies reported a significant decrease in BMD in patients with DTC compared with controls. The other 10 cross-sectional studies reported no significant differences between patients with DTC and controls. Two of the 4 prospective studies reported a significant decrease in BMD in patients with DTC compared with controls.
Postmenopausal women (16 studies).
Four of the 14 cross-sectional studies reported a significant decrease in BMD in patients with DTC compared with controls. The other 10 cross-sectional studies reported no significant differences between patients with DTC and controls. Two of the 4 prospective studies reported a significant decrease in BMD in patients with DTC compared with controls; in one of these studies (a randomised controlled trial) the BMD was unchanged in patients randomised to calcitonin or calcium, but was significantly lower in patients taking placebo.
Men (9 studies).
One of the 8 cross-sectional studies reported that BMD was significantly lower in patients with DTC or Graves disease compared with controls. The only prospective study reported a significant decrease in BMD compared with baseline at the distal radius, but not the femoral neck, in patients with DTC. Findings suggest that postmenopausal women taking TSH-suppressive thyroxine therapy are at greatest risk of reduced BMD. Studies generally found no increased risk of reduced BMD in premenopausal women and men.
Authors' conclusions

CRD commentary
The review addressed a clear question that was defined in terms of the participants, intervention and outcomes; exclusion rather than inclusion criteria were defined for study design. Several relevant sources were searched but no apparent attempts were made to minimise publication or language bias. The assessment of study validity was limited, thus the results from these studies and any synthesis may not be reliable. The methods used to select studies and extract the data were not described, so it is not known whether any efforts were made to reduce reviewer errors and bias.
In view of the diversity of the studies, a narrative synthesis with studies grouped by participants and study design was appropriate. Although the sample size of most studies might have been too small to detect a statistically significant effect on BMD, this point was not highlighted. Lack of reporting of review methods, lack of an adequate quality assessment of the included studies, and a reliance upon studies with small sample sizes make commenting on the reliability of the conclusions difficult.
Implications of the review for practice and research
Practice: The authors stated that postmenopausal women with DTC who are receiving TSH-suppressive thyroxine therapy should be screened when treatment starts, regularly monitored, and treated with bone-protective agent if required.
